EGFR and non-small cell lung carcinoma: Furthermore, downregulation of miR‐483‐3p facilitates acquired gefitinib resistance and epithelial‐to‐mesenchymal transition by targeting integrin β3 in EGFR‐mutant NSCLC (Yue et al., 2018).